{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:59:01Z","timestamp":1780372741295,"version":"3.54.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010363","name":"Minister Erna Hamiltons Legat for Videnskab og Kunst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the influence of comorbidities on treatment response, disease activity and persistence with first-line IL-17 inhibitor (IL-17i) treatment in patients with PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were divided into three groups depending on the presence and\/or severity of comorbidities using the Charlson Comorbidity Index (CCI). Groups were CCI 0: no comorbidities, CCI 1: one comorbidity and CCI \u22652: two or more comorbidities or one or more severe comorbidities. Outcomes in the groups were compared for treatment persistence, treatment response and disease activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A higher CCI score was associated to an elevation in baseline CRP, swollen joint count and frequency of depression and\/or anxiety. The median drug persistence in the groups were CCI 0: 1.8\u2009years, CCI 1: 1.9\u2009years and CCI \u22652: 1.5\u2009years, but was not statistically significant to the CCI score. There were no significant differences in clinical response rates between the groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The presence of comorbidities was associated with increased baseline disease activity and frequency of depression and\/or anxiety, but was not associated with shorter treatment persistence or lower clinical response rates in a cohort of 155 Danish patients with PsA treated with first-line IL-17i.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkad035","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T14:55:13Z","timestamp":1680533713000},"source":"Crossref","is-referenced-by-count":3,"title":["The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study"],"prefix":"10.1093","volume":"7","author":[{"given":"Magnus B","family":"Petersen","sequence":"first","affiliation":[{"name":"Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka L","family":"Hansen","sequence":"additional","affiliation":[{"name":"Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bispebjerg Hospital , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja S","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg , Denmark"},{"name":"DANBIO Registry and Rigshospitalet , Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Frank","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology and Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-7102","authenticated-orcid":false,"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"2023042101274935800_rkad035-B1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00508-016-1111-9","article-title":"An overview of psoriatic arthritis \u2013 epidemiology, clinical features, pathophysiology and novel treatment targets","volume":"128","author":"Kerschbaumer","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"2023042101274935800_rkad035-B2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","article-title":"Societal costs and patients\u2019 experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study","volume":"76","author":"Kristensen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023042101274935800_rkad035-B3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40744-020-00207-6","article-title":"Depression in psoriatic arthritis: dimensional aspects and link with systemic inflammation","volume":"7","author":"Mathew","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2023042101274935800_rkad035-B4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","article-title":"Recognizing and managing comorbidities in psoriatic arthritis","volume":"27","author":"Ogdie","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"2023042101274935800_rkad035-B5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023042101274935800_rkad035-B6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23333","article-title":"Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study","volume":"70","author":"Ballegaard","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023042101274935800_rkad035-B7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CLEP.S99490","article-title":"The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO","volume":"8","author":"Ibfelt","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2023042101274935800_rkad035-B8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2023042101274935800_rkad035-B9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"2023042101274935800_rkad035-B10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1403494810395825","article-title":"The Danish Psychiatric Central Research Register","volume":"39","author":"Mors","year":"2011","journal-title":"Scand J Public Health"},{"key":"2023042101274935800_rkad035-B11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson Comorbidity Index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"2023042101274935800_rkad035-B12","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00296-015-3296-z","article-title":"Comparison of the Charlson Comorbidity Index derived from self-report and medical record review in Asian patients with rheumatic diseases","volume":"35","author":"Ng","year":"2015","journal-title":"Rheumatol Int"},{"key":"2023042101274935800_rkad035-B13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2023042101274935800_rkad035-B14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2023042101274935800_rkad035-B15","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2023042101274935800_rkad035-B16","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1136\/annrheumdis-2018-213463","article-title":"Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?","volume":"77","author":"Michelsen","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkad035\/49732076\/rkad035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/2\/rkad035\/50051244\/rkad035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/2\/rkad035\/50051244\/rkad035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T01:28:02Z","timestamp":1682040482000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkad035\/7100354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4,12]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkad035","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]},"article-number":"rkad035"}}